Macular Hole Progression following Ocriplasmin Intravitreal Injection

Casswell, Edward J.; Fernández‐Sanz, Guillermo; Mitry, Danny; Luk, Sheila; Zakir, Rahila

doi:10.1155/2014/403461

Cited by 8 publications

(6 citation statements)

References 4 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LMH, till now, seems to be an unusual complication [31], while MH formation, according to the MIVI-TRUST trials, can occur in 5.2 % of cases [16]. A possible explanation of FTMH formation is the increased anteroposterior traction on the VMT secondary to the movement of vitreous after injection [32]. In this prospective clinical research, we mainly studied what and when happened in the existing VMT after ocriplasmin injection and for how long the induced concomitant symptoms and findings lasted.…”

Section: Discussionmentioning

confidence: 95%

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Chatziralli

Theodossiadis

Parikakis

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Our study demonstrated a VMT release rate of 66.7 %. Apart from the known baseline factors that influence VMT release after ocriplasmin injection, the size of the vitreofoveal angle, a V-shaped and loose vitreomacular adhesion, a small adhesion area, and thin vitreous strands at the adhesion site, could additionally affect the outcome of VMT release. In addition, we studied when VMT release and concomitant events occur and for how long the induced complications lasted.

show abstract

Section: Discussionmentioning

confidence: 95%

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Chatziralli

Theodossiadis

Parikakis

et al. 2015

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Algunos informes clínicos y pequeñas series de casos manifestaron inquietud acerca de los posibles efectos adversos de la enzima. Estos estudios publicaron información sobre síntomas y resultados clínicos que incluyeron distintos grados de disfunción retiniana, tales como pérdida de agudeza visual, dicromatopsia, nictalopía, estrechamiento del campo visual, anomalías o defectos externos de la señal retiniana en tomografía de coherencia óptica de dominio espectral, crecimiento del agujero macular, desprendimiento macular con acumulación del fluido subretiniano y cambios electrorretinográficos [6,7,[12][13][14][19][20][21][22][23][24][25] .…”

Section: Discussionunclassified

Propiedades biomecánicas de la membrana limitante interna tras recibir tratamiento intravítreo con ocriplasmina

Vielmuth¹,

Schumann²,

Spindler³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

de las muestras de MLI extraídas de ojos con o sin tratamiento con ocriplasmina. Las áreas onduladas de la parte de la retina presentaron una mayor rigidez que la parte del vítreo de la MLI. La cartografía topográfica tanto de la parte del vítreo como de la retina de la MLI no mostró ninguna alteración aparente de la morfología en ojos tratados con ocriplasmina en comparación con los ojos no tratados. La tinción con azul brillante conllevó un aumento de la rigidez tisular. Conclusiones: Las inyecciones intravítreas de ocriplasmina no varían las propiedades biomecánicas de la MLI humana. No existen pruebas de un posible efecto enzimático que interfiera con la rigidez de esta membrana basal. © 2017 S. Karger AG, Basel IntroducciónLa ocriplasmina (Jetrea ® , ThromboGenics, Lovaina, Bélgica) constituye una forma truncada sin especificar y recombinante de la serina proteasa plasmina que posee actividad proteolítica frente a la laminina y fibronectina, ambos componentes principales de la interfase vitreore- Palabras clave Membrana limitante interna · Ocriplasmina · Tracción vitreomacularResumen Objetivo: Evaluar la rigidez de la membrana limitante interna (MLI) humana y evaluar los posibles cambios de las propiedades mecánicas tras administrar una inyección intravítrea de ocriplasmina para tratar la tracción vitreomacular. Métodos: Este estudio se compone de una serie de casos intervencionales y comparativos de 12 muestras de MLI extraídas mediante cirugía y obtenidas de forma consecutiva de 9 ojos de 9 pacientes después de someterse sin éxito a vitreólisis farmacológica con ocriplasmina. Durante el mismo periodo de tiempo, 16 muestras de otros 13 ojos sin tratamiento con ocriplasmina se obtuvieron mediante vitrectomía y sirvieron como controles. Todos los pacientes presentaron agujeros maculares o tracción vitreomacular y se sometieron a vitrectomía con disección de la MLI tanto con tinción con azul brillante (AB) como sin ella. Todas las muestras se analizaron con un microscopio de fuerza atómi-ca con imágenes de las regiones de 25 × 25 μm. En todas las muestras, se analizaron tanto la parte de la retina como la del vítreo de la MLI. Resultados: La microscopia de fuerza atómi-ca no reveló diferencias significativas en cuanto a elasticidad

show abstract

“…Clinical reports and small case series raised concern on potential side effects of the enzyme. These studies reported on clinical symptoms and findings including varying degrees of retinal dysfunction, such as visual acuity loss, dyschromatopsia, nyctalopia, visual field constriction, outer retinal signal abnormalities or defects on spectral domain optical coherence tomography, macular hole enlargement, macular detachment with subretinal fluid accumulation, and electroretinography changes [6,7,12,13,14,19,20,21,22,23,24,25]. …”

Section: Discussionmentioning

confidence: 99%

Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment

Vielmuth

Schumann²,

Spindler³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical properties following intravitreal ocriplasmin injection for vitreomacular traction. Methods: This is an interventional comparative case series of 12 surgically excised ILM specimens consecutively obtained from 9 eyes of 9 patients after unsuccessful pharmacologic vitreolysis with ocriplasmin. During the same time period, 16 specimens from 13 other eyes without ocriplasmin treatment were harvested during vitrectomy and served as controls. All patients presented with macular holes or vitreomacular traction and underwent vitrectomy with ILM peeling either with or without brilliant blue (BB) staining. All specimens were analyzed using atomic force microscopy with scan regions of 25 × 25 μm. In all specimens, both the retinal side and vitreal side of the ILM were analyzed. Results: Atomic force microscopy revealed no significant differences in elasticity of ILM specimens removed from eyes with or without ocriplasmin treatment. Undulated areas of the retinal side presented stiffer than the vitreal side of the ILM. Topographical mapping of both the vitreal and retinal side of the ILM showed no apparent alteration of the morphology in ocriplasmin-treated eyes compared to untreated eyes. Staining with BB resulted in an increase of tissue stiffness. Conclusions: Intravitreal injection of ocriplasmin does not change biomechanical properties of the human ILM. There is no evidence of a potential enzymatic effect of ocriplasmin interfering with the stiffness of this basement membrane.

show abstract

Macular Hole Progression following Ocriplasmin Intravitreal Injection

Cited by 8 publications

References 4 publications

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Propiedades biomecánicas de la membrana limitante interna tras recibir tratamiento intravítreo con ocriplasmina

Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment

Contact Info

Product

Resources

About